|Scientists Identify a Potential Target that May Provide a New Approach to Melanoma Treatment
In a new study released today, researchers have shown that a specific protein
plays an important role in inhibiting the development and spread of melanoma
tumors in mouse and in human skin models. Increased expression of the protein,
SOX9, may also decrease the resistance of melanoma cells to retinoic acid,
which is used to treat several other types of cancer. The ability to increase
sensitivity to retinoic acid by stimulating SOX9 expression could lead to new
approaches for treating melanoma and other cancers. The study, led by researchers
at the National Cancer Institute (NCI), part of the National Institutes of
Health, appears online March 9, 2009, in The Journal of Clinical Investigation.
Melanoma, which begins in cells called melanocytes, is the most deadly form of
skin cancer. Current approaches to treating melanoma include the use of conventional
therapies, such as radiation therapy and chemotherapy, or stimulating the immune
system to inhibit cancer growth.
"Unfortunately, in most cases, those approaches fail to cure patients," said lead author Thierry Passeron, M.D., of NCIís Center for Cancer Research. "For some blood cancers, forms of retinoic acid have provided effective treatments. However, most solid cancers, including melanoma, are resistant to retinoic acid."
The SOX9 protein is a transcription factor expressed in various adult tissues, including the brain, heart, and kidneys. Transcription factors control the expression of genes and, therefore, function as key regulators of important biological processes. In previous work, the researchers demonstrated that SOX9 protein plays a role in regulating the differentiation, or acquisition of mature characteristics, of normal melanocytes, as well as in inhibiting the proliferation of human melanoma cells. Other work with laboratory-grown cancer cells suggests that retinoic acid may play a role in the antiproliferative effects of SOX9.
In the study, the researchers first looked at the expression of SOX9 protein in normal human skin samples and in samples of nevi (precancerous tissue), primary tumors, and metastatic melanoma tumors that had spread to other tissues. They found that the expression of SOX9 is highest in normal cells and is progressively reduced as cells transition from the precancerous state to the most advanced stages of cancer. Next, the researchers inserted the SOX9 gene into human melanoma cells. Using reconstructed skin samples, which contained the human melanoma cells that either had or did not have the inserted gene, the researchers found that cells without the inserted SOX9 gene formed tumors, whereas cells containing the added gene did not. Similar findings were observed in mice that were injected underneath the skin with melanoma cells that either had or did not have the inserted SOX9 gene.
The researchers next determined whether melanoma cells with the inserted SOX9 gene were sensitive to retinoic acid. Indeed, when exposed to retinoic acid, these cells showed a dramatic decrease in proliferation compared to cells without the inserted gene. The sensitivity to retinoic acid appeared to be a consequence of reduced expression of a protein called PRAME, which is a known repressor of the receptor that binds retinoic acid in melanoma cells.
The researchers next investigated whether the SOX9 protein could be activated or its expression increased in melanoma cells. Prostaglandin D2 (PGD2), a naturally occurring molecule in the body, had previously been shown to activate SOX9 protein in human testicular cancer cells, and the researchers found that melanoma cells exposed to PGD2 also had enhanced SOX9 activity. They treated mice with induced melanoma tumors with a substance that simulates the PGD2 biochemical pathway alone, retinoic acid alone, or a combination of the two agents. They found that the combination treatment decreased the size of tumors in the mice to a greater extent than treatment with either single agent alone.
"This study brings new insight into the cellular changes that occur during the development of melanoma and suggests a new therapeutic approach," said senior author Vincent Hearing, Ph.D., of NCIís Center for Cancer Research. "We will also use our models to determine the optimal combinations of agents and forms of retinoic acid to stimulate SOX9. The next clinical steps will be phase I and phase II studies in humans, as our ultimate goal is to treat people affected by this public health burden."
For more information on Dr. Hearingís research, please go to http://ccr.cancer.gov/staff/staff.asp?profileid=5716.
NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI Web site at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
The National Institutes of Health (NIH) — The Nation's
Medical Research Agency — includes 27 Institutes and
Centers and is a component of the U.S. Department of Health and
Human Services. It is the primary federal agency for conducting
and supporting basic, clinical and translational medical research,
and it investigates the causes, treatments, and cures for both
common and rare diseases. For more information about NIH and
its programs, visit www.nih.gov.
Reference: Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y, and Hearing VJ. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J. Clin. Invest. Vol. 119 No. 4.